Supreme Court | GenomeWeb

Supreme Court

The Thermo Fisher subsidiary is not liable to Promega in the US for selling infringing forensic DNA kits in Europe, containing US-manufactured Taq polymerase.

The case is being framed as either upholding a strong patent regime or dealing a blow to US-based manufacturing as part of the global supply chain.

Arti Rai and Colleen Chien are studying whether the Supreme Court's decisions in Mayo v Prometheus and Bilski v Kappos have had a negative impact on diagnostics innovation.

NEW YORK (GenomeWeb) – While industry observers might disagree about whether GeneDx's decision to apply for inter partes review (IPR) of 11 patents held by Myriad Genetics will work in its favor, they generally concur that it is a quicker and less costly strategy than litigation.

This article has been updated to include a statement from Myriad Genetics.

At the San Antonio Breast Cancer Symposium last week, Myriad Genetics presented new data on its myRisk Hereditary Cancer panel, which the firm believes will help it convince physicians, patients, and payors of the advantages of multi-gene panels over single disease testing.

Industry reactions to the US Supreme Court's decision to invalidate patents on isolated gene sequences were immediate and ranged from elation to disappointment.

Women with a family history of breast and ovarian cancer who are interested in getting genetically tested to gauge whether they have a heightened risk for the diseases should speak to a genetic counselor before getting tested, patient groups are advising their members.

NEW YORK (GenomeWeb News) – The US Supreme Court today unanimously ruled that human genes are not patentable, but synthetic DNA, or cDNA, is patent eligible because it does not occur naturally.

Pages

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.